EDIT [NASD]
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-2.69 Insider Own0.50% Shs Outstand68.64M Perf Week-3.35%
Market Cap1.24B Forward P/E- EPS next Y-3.46 Insider Trans-3.24% Shs Float68.40M Perf Month24.55%
Income-184.50M PEG- EPS next Q-0.85 Inst Own70.50% Short Float24.52% Perf Quarter73.64%
Sales31.80M P/S39.10 EPS this Y-43.90% Inst Trans5.04% Short Ratio9.69 Perf Half Y8.56%
Book/sh6.78 P/B2.77 EPS next Y-4.80% ROA-28.40% Target Price32.00 Perf Year-71.28%
Cash/sh6.83 P/C2.75 EPS next 5Y- ROE-34.80% 52W Range9.59 - 73.03 Perf YTD-29.30%
Dividend- P/FCF- EPS past 5Y1.20% ROI-34.90% 52W High-74.30% Beta2.05
Dividend %- Quick Ratio12.70 Sales past 5Y33.40% Gross Margin- 52W Low95.72% ATR1.36
Employees264 Current Ratio12.70 Sales Q/Q4.20% Oper. Margin- RSI (14)61.99 Volatility7.23% 7.82%
OptionableYes Debt/Eq0.00 EPS Q/Q4.30% Profit Margin- Rel Volume0.85 Prev Close18.09
ShortableYes LT Debt/Eq0.00 EarningsAug 03 BMO Payout- Avg Volume1.73M Price18.77
Recom2.60 SMA209.61% SMA5030.19% SMA200-6.44% Volume1,478,069 Change3.76%
Oct-19-21Initiated SVB Leerink Mkt Perform $41
Sep-24-21Initiated Stifel Hold $65
Sep-10-21Upgrade Oppenheimer Perform → Outperform $42 → $80
Aug-09-21Upgrade Truist Hold → Buy $45 → $80
Aug-05-21Upgrade Evercore ISI Underperform → Outperform $20 → $60
Jun-04-21Resumed Robert W. Baird Outperform $44
May-04-21Initiated RBC Capital Mkts Sector Perform $40
Apr-16-21Initiated Goldman Sell $20
Mar-22-21Initiated Credit Suisse Outperform $58
Mar-01-21Downgrade Barclays Overweight → Equal Weight $46
Feb-26-21Downgrade Truist Buy → Hold $45
Jan-19-21Downgrade Morgan Stanley Equal-Weight → Underweight $64 → $45
Jan-07-21Downgrade Raymond James Outperform → Mkt Perform
Dec-10-20Upgrade Wells Fargo Equal Weight → Overweight $69
Nov-03-20Initiated Robert W. Baird Underperform $14
Jun-18-20Resumed SunTrust Buy $45
Feb-21-20Initiated Wells Fargo Equal Weight $28
Apr-12-19Initiated Evercore ISI Outperform
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Outperform $40
Aug-05-22 07:24AM  
Aug-04-22 12:30PM  
Aug-03-22 04:41PM  
07:55AM  
06:29AM  
Jul-27-22 06:30AM  
Jul-26-22 06:26AM  
Jul-21-22 11:11AM  
10:30AM  
Jul-20-22 04:30PM  
Jul-18-22 07:00AM  
Jul-08-22 11:48AM  
10:01AM  
Jun-23-22 06:05AM  
Jun-22-22 08:10AM  
Jun-07-22 07:00AM  
Jun-06-22 04:30PM  
Jun-03-22 11:31AM  
May-18-22 06:45AM  
May-13-22 11:52AM  
10:30AM  
May-12-22 04:30PM  
May-10-22 06:50AM  
May-04-22 01:30PM  
11:54AM  
07:55AM  
06:45AM  
May-02-22 04:31PM  
Apr-27-22 03:03PM  
06:55AM  
Apr-26-22 09:00AM  
Apr-19-22 06:20AM  
Apr-15-22 09:41AM  
Apr-14-22 02:11PM  
07:30AM  
Apr-12-22 11:47AM  
Apr-11-22 09:00AM  
Apr-08-22 01:00PM  
Mar-21-22 07:44AM  
Mar-01-22 04:36PM  
11:26AM  
08:55AM  
Feb-28-22 08:15PM  
04:01PM  
04:15AM  
Feb-25-22 11:51AM  
Feb-24-22 07:45AM  
06:30AM  
Feb-23-22 11:44AM  
09:54AM  
Feb-17-22 05:45PM  
03:03PM  
Feb-16-22 06:15AM  
Feb-11-22 12:02PM  
Feb-08-22 02:15PM  
12:40PM  
Feb-07-22 01:05PM  
09:38AM  
Feb-02-22 06:40AM  
Jan-26-22 05:38PM  
Jan-24-22 01:38PM  
Jan-19-22 10:46AM  
Jan-14-22 11:43AM  
05:19AM  
Jan-13-22 05:24PM  
03:56PM  
Jan-11-22 02:46PM  
Jan-10-22 07:00AM  
Jan-04-22 06:58AM  
Dec-20-21 08:32AM  
07:00AM  
Dec-17-21 10:06AM  
09:04AM  
Dec-16-21 10:00AM  
09:38AM  
Dec-15-21 11:16AM  
Dec-14-21 11:06AM  
Dec-13-21 10:55AM  
Dec-12-21 06:00PM  
Dec-10-21 10:21AM  
Dec-09-21 11:38AM  
Dec-08-21 05:57AM  
Dec-07-21 10:00AM  
10:00AM  
Dec-03-21 10:00AM  
Nov-30-21 05:36AM  
Nov-25-21 10:56AM  
Nov-23-21 12:01PM  
11:52AM  
Nov-22-21 11:23AM  
Nov-17-21 03:01AM  
Nov-16-21 09:08AM  
Nov-12-21 07:00AM  
Nov-09-21 11:00AM  
Nov-08-21 04:00PM  
12:52PM  
08:25AM  
07:00AM  
Nov-05-21 10:09AM  
Nov-04-21 09:02AM  
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Eaton BruceEVP, CHIEF BUSINESS OFFICERAug 09Sale18.602935,44965,128Aug 10 04:30 PM
Shearman Mark SEVP, CHIEF SCIENTIFIC OFFICERJun 15Sale10.065,14551,74568,349Jun 16 04:15 PM
Eaton BruceEVP, CHIEF BUSINESS OFFICERJun 03Sale11.541,12312,95665,421Jun 06 04:46 PM
ROBERTSON MICHELLEEVP, CHIEF FINANCIAL OFFICERJun 03Sale11.541,52717,61782,667Jun 06 04:45 PM
Eaton BruceEVP, CHIEF BUSINESS OFFICERMay 09Sale13.112973,89566,544May 11 04:15 PM
Eaton BruceEVP, CHIEF BUSINESS OFFICERApr 01Sale19.641,25824,70766,841Apr 04 04:30 PM
ROBERTSON MICHELLEEVP, CHIEF FINANCIAL OFFICERMar 03Sale17.3376713,29084,194Mar 07 04:15 PM
Eaton BruceEVP, CHIEF BUSINESS OFFICERMar 03Sale17.334036,98368,386Mar 07 04:15 PM
Eaton BruceEVP, CHIEF BUSINESS OFFICERFeb 08Sale17.633025,32331,196Feb 10 04:36 PM
ROBERTSON MICHELLEChief Financial OfficerJan 11Sale25.701,74444,82131,462Jan 13 04:17 PM
MULLEN JAMES CCEOJan 03Sale26.9518,252491,97975,898Jan 04 04:23 PM
Michaels Lisa AnneEVP/Chief Medical OfficerNov 12Sale38.331,56860,10118,432Nov 15 04:26 PM
Eaton BruceEVP, Chief Business OfficerNov 09Sale40.6128711,65528,026Nov 10 06:52 PM
MULLEN JAMES CCEOOct 18Sale38.0313,805525,03357,673Oct 20 04:16 PM